N-acetyltransferase 2 Slow Acetylator Genotype Associated with Adverse Effects of Sulfasalazine in the Treatment of Inflammatory Bowel Disease | Zendy

Min Chen | Zendy; Bing Xia | Zendy; Bixiao Chen | Zendy; Qiusha Guo | Zendy; Li Jin | Zendy; Mei Ye | Zendy; Zhengguo Hu | Zendy

Open Access

N-acetyltransferase 2 Slow Acetylator Genotype Associated with Adverse Effects of Sulfasalazine in the Treatment of Inflammatory Bowel Disease

Author(s) -

Min Chen,

Bing Xia,

Bixiao Chen,

Qiusha Guo,

Li Jin,

Mei Ye,

Zhengguo Hu

Publication year - 2007

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2007/976804

Subject(s) - sulfasalazine , genotype , medicine , inflammatory bowel disease , gastroenterology , adverse effect , allele , ulcerative colitis , sulfapyridine , arylamine n acetyltransferase , rash , polymorphism (computer science) , disease , biology , gene , genetics , chemistry , organic chemistry

N-acetyltransferase 2 (NAT2) is an important enzyme catalyzing N-acetylation of sulfasalazine (SASP). The aim of the present study was to investigate associations of the genotypes of NAT2 with inflammatory bowel disease (IBD), and with adverse effects of SASP, which is used as the first-line treatment of IBD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research